The Cancer Vanguard is about driving innovation in cancer care.
One innovation coming to cancer treatment right now is biosimilars. However, introducing biosimilars into a Trust can present some challenges. Biosimilars are a relatively new technology that is not always fully understood, especially in oncology. Knowing this, the Cancer Vanguard has done significant work to make sure it gets biosimilar adoption right first time.
The Joint Working Partnership has developed resources and tools (see below) to help the NHS consider any biosimilars, regardless of who makes them.
NHS England has also published a resource on biosimilars: What is a Biosimilar Medicine?
If you are a patient, information on biosimilars will be available soon.
What’s in this resource?
This resource is built around a biosimilar adoption process that the Cancer Vanguard has developed, taking into account other key initiatives around biosimilars in the NHS, including the National Biosimilars Medicines Programme Board (NBMPB). Following this process will help you share in the work and learning of the Cancer Vanguard.
An interactive PDF is available to download that will provide you with the information you will need to help with adoption of biosimilars in your Trust. Within the PDF is a suggested process timeline (see image below), setting out the processes that pharmacy might follow, as well as more general Trust guidance on this. The timeline within the PDF allows you to click through to various tools and templates, created by the Cancer Vanguard team.
The team was comprised of NHS and Sandoz representatives, bringing together their combined expertise in biosimilar adoption to help you introduce biosimilars into your Trust.
You are welcome to download and adapt these resources to make them work in your Trust. These are linked to within the relevant steps in the process timeline which is in the PDF, and are also available below to download separately below.
Click on the image below to download the interactive PDF:
The tools and templates are available via the PDF, or separately:
- Cancer Vanguard biosimilars position statement
- Biosimilars principles – education presentation
- Service impact study
- Education impact assessment
- Biosimilar policy
- General biosimilar patient information template for NHS Trust use
- Lymphoma Association: Biosimilars for lymphoma
- FAQs on biosimilars for clinicians
- UK Medicines information: Answers to commonly asked questions about biosimilar versions of rituximab
The Cancer Vanguard claims a copyright in its works presented at this website. The Cancer Vanguard authorises you to view, copy, download and print The Cancer Vanguard documents on this website, subject to the following conditions:
- The documents may be used solely for personal, non-commercial and informational purposes, they may not be used for commercial gain
- Where identified as modifiable, The Cancer Vanguard must be acknowledged as the source of the document and The Cancer Vanguard and Sandoz must be acknowledged as authors
- Where not identified as modifiable, the following copyright notice and permission notice must appear in each document: “© Copyright 2017 The Cancer Vanguard. All rights reserved.”
- The user is responsible for checking the materials are suitable for their institution before use. The Cancer Vanguard and Sandoz do not accept any liability for damages or injury as a result of the use of the materials held on this website
UK/MKT/SDZ/17-0027a(1) Jun 2017